Movasin injection 10mg / ml 1.5ml amp piece 3


Movasin injection 10mg / ml 1.5ml amp piece 3



Active substance:
1 ml of solution contains: meloxicam – 10 mg.
Sodium chloride, glycine, glikofurfurol (Tetraglycol), poloxamer 188, meglumine (meglumine), Sodium hydroxide, Water for injection.
Product form:
A solution for intramuscular injection of 10 mg / ml in neutral glass ampoules brand HC-3, 1.5 ml. 3, 5 vials are placed in a box made of cardboard. 3, 5 vials are placed in blisters of PVC film and aluminum foil or in blisters of PVC film. 1 contour cell package visit in packs of cardboard.
Hypersensitivity to the active substance or auxiliary components; contraindicated in the post-coronary artery bypass surgery; decompensated heart failure; complete or partial combination of asthma, recurrent nasal polyposis mucous membrane and paranasal sinuses and intolerance to acetylsalicylic kitty items and other non-steroidal anti-inflammatory drugs (NSAIDs) (including history); erosive and ulcerative changes of the gastric mucosa and duodenum 12, active gastrointestinal bleeding; aggravation of inflammatory bowel disease (ulcerative colitis, Crohn’s disease); cerebrovascular bleeding or other bleeding; severe liver failure or active liver disease; severe renal failure in patients not undergoing dialysis (creatinine clearance (CC) of less than 30 ml / min), progressive renal disease including confirmed by hyperkalemia; pregnancy, breast-feeding; Children up to age 18 years.
10 mg / ml
Symptomatic treatment of osteoarthritis;
Symptomatic treatment of rheumatoid arthritis;
Symptomatic treatment of ankylosing spondylitis (Bechterew’s disease).
Interaction with other drugs
If simultaneous reception with other NSAIDs (and acetylsalicylic acid) increases the risk of erosive-ulcerous lesions and bleeding from the gastrointestinal tract.
While the use of antihypertensive drugs may decrease the effectiveness of the latter.
While the use of drugs lithium may develop lithium accumulation and increasing its toxic effect (recommended control the concentration of lithium in the blood).
While the use of methotrexate amplified side effects of the latter on the hematopoietic system (risk of anemia and leukopenia shown periodic blood count control).
While the use of diuretics and cyclosporine increases the risk of renal failure.
While the use of intrauterine contraceptive devices may reduce the effectiveness of the latter.
While the use of anticoagulants (heparin, ticlopidine, warfarin), antiplatelet agents (aspirin, clopidogrel) and a fibrinolytic drugs (streptokinase, fibrinolysin) increases the risk of bleeding (required periodic monitoring parameters of blood clotting).
While the use of selective serotonin reuptake inhibitor increases the risk of gastrointestinal bleeding.
Symptoms: violation of consciousness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, acute renal failure, liver failure, respiratory arrest, asystole.
Treatment: No specific antidote; symptomatic therapy. Forced diuresis, urinary alkalization, hemodialysis – are ineffective due to high drug connection with blood proteins.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug (NSAID).
Meloxicam – a non-steroidal anti-inflammatory drug having analgesic, antiinflammatory and antipyretic action. The anti-inflammatory action due to inhibition of the enzymatic activity of cyclooxygenase-2 (COX-2) involved in the biosynthesis of prostaglandins in inflammation. To a lesser extent meloxicam acts on cyclooxygenase-1 (COX-1) involved in prostaglandin synthesis, protecting the mucosa of the gastrointestinal tract (GIT) and participate in the regulation of renal blood flow.
Relative bioavailability is almost 100%. After intramuscular administration at a dose of 5 mg of the maximum concentration (Cmax) was 1.62 g / ml and is attained within about 60 minutes. Meloxicam binds well to plasma proteins, particularly albumin (99%). Penetrates into the synovial fluid, synovial fluid concentration is about 50% of plasma concentrations. Volume of distribution (Vd) is low, an average of 11 liters. Interindividual differences account for 30-40%. Meloxicam is almost completely metabolized in the liver to form 4 pharmacologically inactive derivatives. The main metabolite, 5`-karboksimeloksikam (60% of the dose), is formed by oxidation of an intermediate metabolite, 5`-Hydroxy-metilmeloksikama which is also excreted, but to a lesser extent (9% of the dose). In vitro studies have shown that this metabolic transformation plays an important role isoenzyme SYR2S9, the added value has isoenzyme SYR3A4. The formation of two other metabolites (components, respectively, 16% and 4% of the dose) participates peroxidase activity which probably varies individually. Derived equally from feces and urine, mainly as metabolites. In unmodified form with the faeces derived at least 5% of the daily dose in the urine in an unmodified form of the drug is found only in trace amounts. The average half-life (T1 / 2) was 20 hours. Plasma clearance is an average of 8 ml / min. Meloxicam exhibits linear pharmacokinetics in doses of 7.5-15 mg when administered intramuscularly. Hepatic or renal failure average weight has no significant influence on the pharmacokinetics of meloxicam.
Pregnancy and breast-feeding
Conditions of supply of pharmacies
On prescription.
side effects
From the digestive system: more than 1% – indigestion, including nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea; 0.1-1% – transient increase in “hepatic” enzymes, hyperbilirubinemia, belching, esophagitis, gastroduodenal ulcer, bleeding from the gastrointestinal tract (including hidden), stomatitis; less than 0.1% – perforation of the gastrointestinal tract, colitis, hepatitis, gastritis.
From hemopoiesis system: more than 1% – anemia; 0.1-1% – changes in blood counts, including leukopenia, thrombocytopenia.
For the skin: more than 1% – itching, skin rash; 0.1-1% – urticaria; less than 0.1% – photosensitivity, bullous eruptions, erythema multiforme, including Stevens-Johnson syndrome, toxic epidermal necrolysis.
The respiratory system: less than 0.1% – bronchospasm.
Central nervous system (CNS): more than 1% – dizziness, headache; 0.1-1% – vertigo, tinnitus, drowsiness; less than 0.1% – confusion, disorientation, emotional lability.
On the part of the cardiovascular system (CVS): more than 1% – peripheral edema; 0.1-1% – increase in blood pressure (BP), heart rate, “tides” of blood to the skin.
From the urinary system: 0.1-1% – hypercreatininemia and / or an increase in urea in blood serum; less than 0.1% – acute renal failure; connection with the intake of meloxicam is not installed – interstitial nephritis, albuminuria, hematuria.
From the senses: less than 0.1% – conjunctivitis, visual disturbances, including blurred vision.
Allergic reactions: less than 0.1% – angioneurotic edema, anaphylactic / anaphylactoid reactions.
Local reactions: more than 1% – swelling at the injection site; less than 1% – soreness at the injection site.
special instructions
Caution should be exercised when using the drug in patients with a history in which the gastric ulcer and duodenal ulcers, as well as in patients on anticoagulant therapy. In these patients, increased risk of erosive and ulcerative diseases of the gastrointestinal tract.
Care should be taken to monitor renal function when using the drug in elderly patients, patients with chronic heart failure to clinical manifestations in patients with cirrhosis, and in patients with hypovolemia resulting from surgical procedures.
In patients with renal failure, if CC 30 ml / min is required dosing regime correction.
Patients on dialysis, drug dosage should not exceed 7.5 mg / day.
Patients taking both diuretics and meloxicam, should take plenty of fluids.
If during treatment with any allergic reactions (itching, skin rash, urticaria, photosensitivity) should consult a doctor with a view to resolving the issue of the steroid is discontinued.
Meloxicam, like other NSAIDs, may mask the symptoms of infectious diseases.
Use of meloxicam, as well as other drugs that block the synthesis of prostaglandins, can affect fertility, it is not recommended for women planning pregnancy.
Storage conditions
In a dry, dark place at a temperature not higher than 30 C. Keep out of reach of children.
Dosing and Administration
Intramuscular administration of the preparation is shown only for the first 2-3 days. Subsequently treatment continued with oral forms (tablets). The recommended dose is 7.5 mg or 15 mg of 1 time / day, depending on the intensity of the pain and the severity of the inflammatory process. The drug is administered by deep intramuscular injection.
Intravenous administration of the drug is prohibited!
In patients with increased risk of adverse reactions, the daily dose should not exceed 7.5 mg.
Patients with end stage renal failure, hemodialysis, should not exceed 7.5 mg dose. In patients with small or moderate renal impairment (creatinine clearance of more than 30 ml / min) dose should not exceed 7.5 mg.
drug dosing regime for intramuscular injection in children and adolescents is not defined, this dosage form may only be used in adult patients. The maximum recommended daily dose – 15 mg.
In the combined application of different drug dosage forms its maximum daily dose in tablets, suppositories and in the form of solution for injection of 15 mg.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review